0
0
Subtotal: $0.00
No products in the cart.
Soluble Biotech : Our Companies :
TumorGenesis

TumorGenesis

TumorGenesis Inc. specializes in media that help cancer cells grow outside the patient’s body and retain their DNA/RNA and proteomic signatures. With this tool, researchers are able to expand and study cancer cell types inherent in blood tumors and organ systems of all mammals, including humans. This platform, along with other proprietary FDA-approved technologies from Helomics, is used to fuel unique and more clinically actionable data for our predictive models.

Visit TumorGenesis.net

25

Ovarian cancer cell lines

90%

of ovarian cancers represented

View products and solutions now at TumorGenesis

Let us tell you about TumorGenesis.

TumorGenesis will transform cancer diagnosis and treatment via a three-pronged approach: our unique media, discovery kits and AI.

By “fooling” cancer cells into behaving as if they are in a patient’s body, we help research to be more effective to human response. AI enables us to link our patient-derived tumors to patient therapies faster than humanly possible otherwise.

Clinical
Testing


Helomics helps to personalize patient therapies

Drug
Discovery


Helomics database of 150K tumors aids in reducing discovery timeline

Oncology
Research


TumorGenesis develops living tumors outside the body for study and testing

Drug
Development


Soluble Biotech supplies formulations for delivery of therapeutics and vaccines

Cell
Cultures


zPREDICTA utilizes tumor-specific 3D cell culture models, enabling more successful drug development

What problems do we solve?

TumorGenesis makes living tumors readily available to researchers.

TumorGenesis develops ex vivo models that mimic and retain the signature of the tumor as if it were still inside the patient. Contact us to find out how we can help you establish meaningful ex vivo cell models.
At TumorGenesis we search for cancer cell variants and can isolate and grow them without significantly impacting their signatures. Once isolated, the separated sub clonal colonies can be recombined to study drug interactions, cross talk, and unique opportunities for exploitation. The goal is to provide the best home for the cancer cells that includes the right media, the right matrix, and the right biomarkers. Give us a call to discuss how TumorGenesis researchers can help you zero in on meaningful information from cancer cells that will translate to patient treatment.
At TumorGenesis, we will have access to 150,000 patient tumor samples, some of them frozen, some in paraffin blocks, and others with isolated cancer cell samples that have already been screened against chemotherapy compounds. Combining that information as the first early database in new cancers, helps us focus on the rapid development of media, matrix, and biomarkers. Contact us about the cancer you and your team would like to investigate. We can help create reliable, validated, and reproducible cancer cell libraries that do represent the patient tumor.
At TumorGenesis we are developing a ‘rapid screening’ methodology and tool that can be used to quickly and cost effectively screen out the hidden and deadly sleepers and passengers from the actively growing tumor cells. Once they are identified, patients with that profile may be selected or rejected or sent to a different treatment protocol. These rapid tests will eventually be used in every clinical pathology lab for categorizing, rapidly, a patient’s heterogeneous tumors and once linked to our database of responders and non-responders, become even more meaningful to the patient, oncologist, and pathologist. Call us now for a discussion on how we can help build a rapid screen system for your clinical trials.

What are our major offerings?

TumorGenesis provides the fastest and most effective means to develop tumors for research study. Our portfolio of 25 ovarian cancer cell lines covers more than 90% of all documented strains of this disease. 

Primary ovarian cancer​
maintenance media​


View Product

 

Transformed
Breast Media​​


View Product

 

Primary T-cell
leukemia media


View Product

 

LET’S WORK TOGETHER

TumorGenesis corporate contacts:

Sales, Business Development,
and Site Leader

Richard Gabriel
Email
781-883-6639

Project Director

Tony Frudakis, Ph.D
Email
(941) 348-7008
(Leave voicemail)

Lawrence J. DeLucas, PhD

VP, OPERATIONS,
Predictive Oncology
Site Leader, Soluble Biotech
At Predictive Oncology

Dr. DeLucas is the Vice president of Operations for Predictive Oncology and President and co-founder of Soluble Biotech, Inc. DeLucas is currently working to complete development of GMP facilities at Soluble Biotech and at TumorGenesis. In addition, he oversees Soluble Biotech’s solubility and stability contracts for numerous pharmaceutical/biotech companies.

Before Predictive Oncology

From 1981-2016 Dr. DeLucas was a faculty member at the University of Alabama at Birmingham (UAB) where he served as a Professor in the School of Optometry, Senior Scientist and Director of the Comprehensive Cancer Center X-ray Shared Facility, and Director of the Center for Structural Biology. Dr. DeLucas received five degrees from UAB culminating in a Doctor of Optometry degree and a Ph.D. degree in Biochemistry. He also received honorary Doctor of Science degrees from The Ohio State University, Ferris State University, the State University of New York (SUNY), and the Illinois College of Optometry. He has published 164 peer-reviewed research articles in various scientific journals, co-authored and edited several books on protein crystal growth and membrane proteins and is a co-inventor on 43 patents involving protein crystal growth, novel biotechnologies and structure-based drug design. DeLucas was a payload specialist NASA astronaut and member of the 7-person crew of Space Shuttle Columbia for Mission “STS-50”, called the United States Microgravity Laboratory-1 (USML-1) Spacelab mission. Columbia launched on June 25, 1992, returning on July 9.  In 1994 and 1995, Dr. DeLucas served as the Chief Scientist for the International Space Station at NASA Headquarters in Washington, D.C. In 1999, Dr. DeLucas was recognized as one of the scientists who could shape the 21st century in an article published by “The Sunday Times” of London titled “The Brains Behind the 21st Century”.  In 2004, he was recognized as a Top Ten Finalist for the Entrepreneur of the Year award from the Birmingham Business Journal. 

“ Soluble Biotech is continually demonstrating to pharmaceutical and biotech companies the significant value of its novel HSC technology for optimizing protein therapeutic formulations to treat a variety of chronic and infectious diseases. ”

Education
  • Five degrees from Univ. of Alabama at Birmingham (UAB): B.S. Chemistry, M.S. Chemistry, B.S. Physiological Optics, O.D. Optometry, PhD Biochemistry

  • Published 164 peer-reviewed research articles in various scientific journals

  • 1993-2016: Director of the UAB Comprehensive Cancer Center X-ray Shared Facility, and Director of the Center for Structural Biology.

  • NASA Astronaut, flew on Columbia Space

  • 994-1995: Appointed Chief Scientist for the International Space Station at NASA HQ

    • TumorGenesis

    CHIEF EXECUTIVE OFFICER
    Predictive Oncology
    At Predictive Oncology
    This paragraph will outline the executive’s role at PO. This paragraph will outline the executive’s role at PO. This paragraph will outline the executive’s role at PO. This paragraph will outline the executive’s role at PO. This paragraph will outline the executive’s role at PO. This paragraph will outline the executive’s role at PO. This paragraph will outline the executive’s role at PO.
    Before Predictive Oncology
    This paragraph will outline the executive’s role at PO. This paragraph will outline the executive’s role at PO. This paragraph will outline the executive’s role at PO. This paragraph will outline the executive’s role at PO. This paragraph will outline the executive’s role at PO. This paragraph will outline the executive’s role at PO. This paragraph will outline the executive’s role at PO.

    “ Eliminating cancer is our overall goal.  This is not an easy task.  We are working hard every day to make this happen, using our novel technology and talented team of employees. ”

     

     

    Education

    University of Southern California
    School of Business
    MBA, Finance

    University of Colorado Boulder
    BS, Accounting

    Richard Gabriel, BS, MBA

    SVP, RESEARCH & DEVELOPMENT
    Predictive Oncology
    Site Leader, TumorGenesis
    At Predictive Oncology
    My role at Predictive Oncology is to bring the business sense to managing Research and Development programs at all our companies. To seek new ways and opportunities to commercialize exciting new technologies that we have built, licensed, acquired, or are developing through our own research and development. The success of any company is to get the research off the bench and to the customers. That is what I do at POAI and help the other companies as well.
    Before Predictive Oncology
    Prior to starting his first company in 1984 and registering with the FDA a pilot plant facility to make pharmaceutical actives, Mr. Gabriel managed a $50 million product line for W.R. Grace, developed new marketing and sales strategies for Ventron a Division of Morton Thiokol, research work at Ashland Chemical for pressure sensitive adhesives and plant scale-up. Since then, he ran a genetics company, built three GMP/Research facilities, and helped 5 drugs reach their markets in AIDS and cancer. Real expertise in cGMP process scale-up and compliance. Completely understand the needs of an API manufacturing facility and build processes that are scalable, environmentally acceptable, and safe. 3 FDA inspections with no 483’s, ISO certification, DEA registration, DoD compliance, NCI contractor and inventor. Has also broad-based experience in start-up companies and how to make them operational and profitable. 7 years of Team set-up, R&D management, and implementation for 165-person (85 PhD’s and Engineers) company (Pharm-Eco) and lecturer on cGMP and Teams within the Pharmaceutical Industry.
    “ Patients are always first, is our driving force. Oncology is a tough space, and we are determined to bring the best validated science to help cancer patients and as our CEO says; “Eliminate Cancer”. You first must know your enemy before you can defeat them. That takes teamwork and a lot of smart hard-working people, our team members at POAI are up to the challenge. ”

     

     

    Education
    Suffolk University
    Executive MBA Program

    Ohio Dominican College
    BS, Chemistry

    Ohio State University
    Microbiology and Virology

    University of Cincinnati
    Associates Degree, Liberal Arts

    Mark A Collins, Ph.D

    SCIENTIFIC/CUSTOMER DEVELOPMENT
    Predictive Oncology
    Chief Technical Officer, Helomics
    At Predictive Oncology

    Mark is currently Chief Technical Officer at Predictive Oncology. Using the power of AI, Mark is responsible for leveraging Helomics’ vast repository of physical and digital tumor samples, to build multi-omic predictive models of tumor drug response and outcome. Such models can be applied to the discovery of new targeted therapies for cancer as well as used in clinical decision support to help oncologists individualize  treatment.

    Before Predictive Oncology

    Dr. Mark Collins embarked on a career in the pharmaceutical industry following his postdoctoral work. Pursuing a passion for both biology and computing, Mark has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the artificial intelligence (AI) machine learning (ML) and drug discovery space. Mark relocated to the USA in 2001 to work for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content cell analysis market, building, and commercializing several key informatics and bioinformatics products.

    Since leaving Thermo Fisher, Mark has focused on developing and commercializing informatics solutions for clinical and translational research, specifically in the specimen tracking, ‘omics data management and NGS analysis space, through key roles at BioFortis, Global Specimen Solutions and Genedata

    “ I have been pursuing a vision since the late 1990s that AI will help deliver better patient therapies. I firmly believe at POAI we will deliver on that vision. ”

    Education
    University of Surrey, UK
    Ph.D., Microbiology

    University of Wolverhampton, UK
    Undergraduate Degree, Applied Science

    Bob Myers

    CHIEF FINANCIAL OFFICER
    Predictive Oncology
    Site Leader, Skyline Medical
    At Predictive Oncology

    Executive officer, Compliance Officer, Corporate Secretary, and member of the Senior Leadership Team. Responsible for Finance, Administration, Human Resources, Investor Relations, and IT. Skyline Medical Site Leader.

    Before Predictive Oncology

    Numerous years as CEO/Controller consultant including medical devices companies. Executive positions with CES Computer Solutions, Computer Accomplishments, Hi-Tech Stationary & Printing, Capital Distributors Corp, International Creative Management American Express, Showtime Entertainment and public accounting with Laventhol & Horwath, CPA’s.

    “ It’s a privilege to work with a highly talented team to pursue oncology advances, while protecting and increasing shareholder value. ”

    Education

    Adelphi University
    MBA, Finance

    Hofstra University
    BBA, Public Accounting 

    J. Melville (“Mel”) Engle

    CHIEF EXECUTIVE OFFICER
    & CHAIRMAN OF THE BOARD
    Predictive Oncology
    At Predictive Oncology
    Mr. Engle became POAI’s CEO in 2021 and was appointed to the POAI Board of Directors in 2016. He was elected Chairman of the Board in 2020.
    Before Predictive Oncology
    Between 2012 and 2021, he was CEO of Engle Strategic Solutions, a consulting and coaching company focused on CEO issues. From 2009 to 2012, he was CEO and Chairman of Thermogenesis, a cell separation company. From 2002 to 2007, he was Regional Head/Director, North America at Merck Generics and CEO of Dey Laboratories, a respiratory company From 1996 to 2001, he was CEO and Chairman of Anika Therapeutics, an orthobiologics company From 1980 to 1995, he was with Allergan, Inc., an eye and skin care company, where he served as CFO, Managing Director (living in Toronto), and other positions with the firm

    “ Eliminating cancer is our overall goal.  This is not an easy task.  We are working hard every day to make this happen, using our novel technology and talented team of employees. ”

    Education

    University of Southern California
    School of Business
    MBA, Finance

    University of Colorado Boulder
    BS, Accounting